此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

阿司匹林在亚临床冠状动脉疾病中的应用:一项试点随机对照试验 (ASCAD-P)

2026年11月10日 更新者:Guillaume Marquis-Gravel、Montreal Heart Institute

In patients with subclinical coronary artery disease, the ASCAD-P study aims to assess the feasibility of a larger phase 3 pragmatic randomized controlled trial comparing prescription versus no prescription of low-dose aspirin in routine clinical practice.

研究概览

详细说明

Cardiovascular disease remains the leading cause of mortality worldwide. Recent large randomized trials have demonstrated limited net clinical benefit of aspirin in unselected primary prevention populations, leading to guideline recommendations against its systematic routine use for cardiovascular protection.

Patients with subclinical coronary artery disease represent a high-risk subgroup. These individuals have documented coronary artery disease but have not experienced overt cardiovascular events or undergone revascularization. Observational data suggest that this population carries a substantially increased risk of myocardial infarction compared with individuals without coronary atherosclerosis. However, the benefit-risk balance of aspirin in this intermediate-risk group remains uncertain

Primary Objective:

To evaluate the recruitment rate of a pilot randomized trial comparing low-dose aspirin prescription versus no prescription.

Secondary Objectives

To evaluate key feasibility metrics, including:

  • The proportion of eligible patients who are randomized;
  • Adherence and persistence to the assigned intervention at 12 months;
  • The proportion of patients who do not complete the 12-month follow-up;
  • Barriers to recruitment, adherence, and retention.

Exploratory Objectives:

To explore clinical outcomes at 12 months, including:

  • The incidence of clinically significant bleeding events (BARC type 2, 3, or 5) and bleeding site;
  • The incidence of major adverse cardiovascular events (MACE), defined as a composite of all-cause mortality, non-fatal myocardial infarction, non-fatal stroke, or coronary revascularization;
  • Individual components of the composite endpoint;
  • Cardiovascular mortality;
  • Adverse Events and Serious Adverse Events.

研究类型

介入性

注册 (估计的)

48

阶段

  • 第三阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

学习地点

    • Quebec
      • Montreal、Quebec、加拿大、H1T 1C8
        • 招聘中
        • Montreal Heart Institute
        • 首席研究员:
          • Guillaume Marquis-Gravel, MD, MSc
        • 接触:
        • 接触:
        • 首席研究员:
          • Pierre Elias, MD
        • 首席研究员:
          • Cyril Gagnon, MD
        • 首席研究员:
          • Alino Demean Loghin, MD
      • Québec、Quebec、加拿大、G1V 4G5
        • 尚未招聘
        • Institut universitaire de cardiologie et de pneumologie de Québec (IUCPQ)
        • 首席研究员:
          • Tomas Cieza, MD
        • 首席研究员:
          • Roubie Dib, MD
        • 接触:
        • 接触:
        • 首席研究员:
          • Sara Desjardins, MD
      • Trois-Rivières、Quebec、加拿大、G8Z 3R9
        • 尚未招聘
        • Centre hospitalier affilié universitaire régional (CHAUR)
        • 首席研究员:
          • Vincent Spagnoli, MD
        • 接触:
        • 首席研究员:
          • Farzin Brian Haghighat

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

40年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  1. Documented coronary atherosclerosis, as defined by one of the following criteria:

    1. Coronary artery calcium (CAC) score > 0;
    2. Cardiac CT angiography (CCTA) / CoroScan: lesions <70% in the right coronary (RCA), left anterior descending (LAD), and circumflex (Cx) arteries or their branches, and <50% in the left main coronary artery;
    3. Coronary angiography: lesions <70% in the right coronary (RCA), left anterior descending (LAD), and circumflex (Cx) arteries or their branches, and <50% in the left main coronary artery; if performed, physiological coronary assessments (FFR, dPR, iFR, etc.) and intracoronary imaging (IVUS or OCT) must be negative for significant disease.
  2. Willing and able to provide informed consent and comply with study procedures

Exclusion Criteria:

  1. History of myocardial infarction (MI), coronary revascularization, stroke, transient ischemic attack (TIA), or peripheral arterial revascularization procedure;
  2. Current prescription or clear indication for aspirin, low-molecular-weight heparin (LMWH), direct oral anticoagulants, or any other antithrombotic medication;
  3. Clear contraindication to aspirin;
  4. History of significant bleeding within the past year;
  5. Severe illness with limited life expectancy (i.e., <5 years);
  6. Any condition that, in the investigator's judgment, would make participation unsafe for the patient.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:预防
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Low-dose Aspirin Prescription

Aspirin 81 mg orally once daily prescription

Aspirin 81 mg orally once daily

其他:No Prescription

No prescription of aspirin 81 mg orally once daily

No prescription of aspirin 81 mg orally once daily

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Monthly Recruitment Rate
大体时间:12 months following study enrollment initiation

Average monthly patient recruitment rate:

0 ≤ Mean rate (patients/month) < 2 = study not feasible; 2 ≤ Mean rate (patients/month) < 4 = study feasible with protocol modifications;

≥ 4 Mean rate (patients/month) = study feasible without major protocol modifications.

12 months following study enrollment initiation

次要结果测量

结果测量
措施说明
大体时间
招募、依从性和患者保留的障碍
大体时间:从招募到随访结束(12个月)
从招募到随访结束(12个月)
Proportion of Eligible Patients Randomized
大体时间:12 months following study enrollment initiation

Proportion of eligible patients who are randomized:

0% ≤ Proportion < 30% = study not feasible, major protocol modifications required; 30% ≤ Proportion < 61% = study feasible with protocol modifications;

≥ 61% = study feasible without protocol modifications.

12 months following study enrollment initiation
Intervention Adherence
大体时间:From randomization to the end of follow-up (12 months)

Proportion of days on which patients take the assigned intervention (adherence):

0% ≤ Mean proportion < 25% = study not feasible, major protocol modifications required; 25% ≤ Mean proportion < 74% = study feasible with protocol modifications;

≥ 74% = study feasible without protocol modifications.

From randomization to the end of follow-up (12 months)
Intervention Persistence
大体时间:From randomization to end of follow-up (12 months)

Proportion of patients who still take the assigned intervention at 12 months of follow-up (persistence):

0% ≤ Proportion < 25% = study not feasible, major protocol modifications required; 25% ≤ Proportion < 70% = study feasible with protocol modifications;

≥ 70% = study feasible without protocol modifications.

From randomization to end of follow-up (12 months)
Proportion of Patients Lost to Follow-up
大体时间:End of follow-up (12 months)

Proportion of patients who do not complete the 12-month follow-up visit:

≥ 10% = study not feasible, major protocol modifications required; 6% ≤ Proportion < 10% = study feasible with protocol modifications; 0% ≤ Proportion < 6% = study feasible without protocol modifications.

End of follow-up (12 months)

其他结果措施

结果测量
措施说明
大体时间
出血率(BARC 2、3、5)
大体时间:从入组到随访结束(12个月)
从入组到随访结束(12个月)
不良事件(AE)发生率和严重不良事件(SAE)发生率
大体时间:从入组至随访结束(12个月)
从入组至随访结束(12个月)
Major Adverse Cardiovascular Event (MACE) Rate
大体时间:From enrollment to the end of follow-up (12 months)

MACE rate (all-cause mortality, non-fatal myocardial infarction, non-fatal stroke, or coronary revascularization) at 12 months of follow-up

From enrollment to the end of follow-up (12 months)

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年7月21日

初级完成 (估计的)

2027年7月21日

研究完成 (估计的)

2028年1月1日

研究注册日期

首次提交

2026年4月5日

首先提交符合 QC 标准的

2026年4月5日

首次发布 (实际的)

2026年4月13日

研究记录更新

最后更新发布 (实际的)

2026年11月12日

上次提交的符合 QC 标准的更新

2026年11月10日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

未定

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

在美国制造并从美国出口的产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅